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Abstract
Skp2 over-expression has been observed in many human cancers. However, the mechanisms
underlying elevated Skp2 expression have remained elusive. We recently reported that Akt1, but
not Akt2, directly controls Skp2 stability by interfering with its association with APC/Cdh1. As a
result, Skp2 degradation is protected in cancer cells with elevated Akt activity. This finding expands
our knowledge of how specific kinase cascades influence proteolysis governed by APC/Cdh1
complexes. However, it awaits further investigation to elucidate whether the PI3K/Akt circuit
affects other APC/Cdh1 substrates. Our results further strengthen the argument that different Akt
isoforms might have distinct, even opposing functions in the regulation of cell growth or migration.
In addition, we noticed that Ser72 is localized in a putative Nuclear Localization Sequence (NLS),
and that phosphorylation of Ser72 disrupts the NLS and thus promotes Skp2 cytoplasmic
translocation. This finding links elevated Akt activity with the observed cytoplasmic Skp2 staining
in aggressive breast and prostate cancer patients. Furthermore, it provides the rationale for the
development of specific Akt1 inhibitors as efficient anti-cancer therapeutic agents.
Introduction
In dividing cells, the cell cycle is tightly controlled by mul-
tiple regulatory mechanisms to ensure that DNA is faith-
fully replicated only once in the S phase and then
distributed equally between two daughter cells in the M
phase. Defective cell cycle regulation can lead to genomic
instability, which ultimately facilitates cancer develop-
ment. Many key regulators governing the cell cycle pro-
gression are short-lived proteins, and selective
degradation of these regulators by the ubiquitin-proteas-
ome system has recently been shown to be a major mech-
anism for ensuring ordered and coordinated cell cycle
progression [1,2]. Moreover, the irreversible nature of
proteolysis guarantees the uni-directional execution of the
cell cycle program, driving the cell cycle from one stage to
the next. There are two related, multi-subunit E3 ubiqui-
tin ligase enzymes, the Anaphase Promoting Complex
(APC) and the Skp1-Cullin1-F-box complex (SCF) that
are considered to be the major driving forces governing
proper cell cycle progression [3]. SCF is active from the
late G1 phase until the G2 phase and mediates the ubiq-
uitination of G1 cyclins and Cdk inhibitors. SCF consists
of the invariable components Skp1, Cul1, and Rbx1, as
well as a variable component known as an F-box protein
that is responsible for substrate recognition. There are 68
putative F-box proteins encoded in the human genome
which can form individual SCF complexes, each with dif-
ferent F-box proteins incorporated into the core Skp1/
Cullin-1-Rbx1 complex [4]. The diversity of these SCF
complexes ultimately provides the high stringency neces-
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sary for substrate specificity. The well-characterized F-box
proteins Skp2, Cdc4/Fbw7, and β-Trcp1 target p27 [5],
cyclin E [6,7], and Cdc25A [8,9], respectively, for ubiqui-
tination and degradation. In all cases, proper phosphor-
ylation of the substrate is required for interaction with the
F-box proteins. Unlike SCF, APC is active from the late G2
phase to the mid-G1 phase, and is responsible for the deg-
radation of mitotic cyclins, securin, and geminin.
Although APC is composed of 11 subunits, the general
structure is very similar to SCF. The substrate adaptors
Cdc20 and Cdh1 are equivalent to the F-box proteins, but
both Cdh1 and Cdc20 do not require post-translational
modification of their respective substrates for recognition,
instead, binding to their substrates via Destruction Boxes
(D-Box) or KEN Boxes.
Skp2 was originally identified as an S-phase Kinase Cdk2/
Cyclin A-associated protein [10]. Subsequently, the iden-
tification of an F-box domain within its coding sequence
suggested the presence of E3 ubiquitin ligase activity
[5,11]. Besides its major downstream target p27, recent
studies have demonstrated that the Skp2/SCF complex
also targets numerous other substrates for degradation,
many of which are negative cell cycle regulators. These
include p21, p57, p130 and FOXO1 [1]. p27 functions as
a tumor suppressor such that its inactivation predisposes
mice to cancer development [12]. However, in contrast
with known tumor suppressor genes such as p53 or Rb,
homozygous loss or silencing of the p27 gene is rarely
found in human cancers. Instead, it is reduced p27 pro-
tein expression which is often linked to human malig-
nancy, suggesting that regulation occurs mainly at the
post-translational level [13]. Indeed, elevated Skp2
expression is frequently observed in many tumors includ-
ing breast and prostate carcinomas [14,15]. It has been
proposed that enhanced Skp2 expression leads to the
accelerated degradation of targets such as p27 and other
cell cycle regulators, thus promoting cell cycle progression
and favoring transformation. Furthermore, overexpres-
sion of Skp2 facilitates transformation of Rat1 cells in soft
agar and in nude mouse xenografts [14]. The oncogenic
potential of Skp2 is further illustrated in transgenic mice.
In one report, overexpression of Skp2 in the mouse pros-
tate induced hyperplasia, dysplasia and low-grade carci-
noma [16], while others have reported that Skp2
transgenic mice co-expressing N-Ras develop lymphomas
[17]. These findings support the contention that Skp2
overexpression inversely correlates with low p27 expres-
sion, and positively correlates with tumor malignancy and
poor diagnosis.
However, the molecular mechanisms underlying elevated
Skp2 expression have not been fully explored. We and
others have previously demonstrated that Cdh1 is the
upstream E3 ubiquitin ligase which promotes Skp2
destruction [18,19]. In contrast to the frequency of Skp2
overexpression, loss of Cdh1 is not a frequent event in
human cancer. Thus, loss of Cdh1 cannot explain the
observation of elevated Skp2 levels in carcinomas. On the
other hand, hyperactivation of the Akt pathway through
various means of genetic alterations is considered a hall-
mark of many cancers. Furthermore, it has been reported
that activation of the PI 3-K (phosphoinositide 3-kinase)/
Akt pathway enhances p27 destruction [20]. This suggests
that sustained Akt activity can influence Skp2 activity.
Consistent with this, studies have also demonstrated that
Akt can contribute to Skp2 overexpression, although the
mechanism has not been explored [21,22].
The Akt family of kinases is composed of three closely
related family members designated Akt1, Akt2 and Akt3,
also known as PKBα (Protein Kinase B), PKBβ and PKBγ,
respectively. Akt isoforms are known to play critical roles
in many cellular processes including proliferation, trans-
formation, survival and metabolism [23]. The PI 3-K and
Akt pathway is frequently amplified and hyperactivated in
most human cancers [24]. Upon activation of receptors
for growth factors such as IGF-1 (insulin-like growth fac-
tor-1), activation of PI 3-K leads to the synthesis of the sec-
ond messenger PtdIns-3,4,5-P3 which binds and recruits
Akt to the plasma membrane. Phosphorylation of Akt by
upstream kinases fully activates the enzyme allowing it to
phosphorylate multiple substrates which contain a mini-
mal motif usually comprising RxRxxS/T (hereby x is any
amino acid) [23]. Akt activity is negatively regulated by
two tumor suppressors, the PTEN lipid phosphatase
which dephosphorylates PtdIns-3,4,5-P3  [25], and
PHLPP, a Ser/Thr phosphatase which dephosphorylates
Akt at Ser473, leading to its inactivation [26]. Since most
of the upstream regulators and downstream mediators of
the Akt pathway are either oncogenes or tumor suppres-
sors, it is not surprising to find that Akt activity is abnor-
mally elevated in most human cancers [27]. Major
mechanisms described to date which explain hyperactiva-
tion of Akt include loss-of-function mutations in PTEN, as
well as gain-of-function mutations in upstream regulators
such as the receptors HER2, EGF-R and Ras [28]. In addi-
tion, constitutively active PI 3-K mutations have been
identified in several human cancers and shown to be caus-
ally linked to elevated Akt signaling [29]. Enhanced Akt
signaling in tumor cells can suppress apoptosis by pro-
moting the phosphorylation and subsequent cytoplasmic
localization of many downstream pro-apoptotic target
proteins such as Bad [30], FOXO1 [31] and FOXO3a [32].
Akt upregulation can also promote cell growth by inacti-
vating the negative cell cycle regulators p21 [33] and p27
[34-36]. Most studies that have explored a role for the PI
3-K and Akt pathway in cell cycle progression, survival
and cancer progression have generally assumed that all
three isoforms function in a overlapping and redundantCell Division 2009, 4:11 http://www.celldiv.com/content/4/1/11
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manner. However, recent studies have begun to suggest
isoform-specific functions for Akt. This was first high-
lighted by distinct phenotypes born out from the Akt1
and Akt2 knockout mice [37]. At the level of signaling and
cell cycle progression, Akt1 has been shown to promote
cell cycle progression, whereas Akt2 promotes cell cycle
exit in myoblasts [38]. The PHLPP1 and PHLPP2 isoforms
differentially dephosphorylate Akt1 and Akt2 leading to
distinct accessibility of each Akt isoform to substrates such
as p27, FOXO3a and GSK-3 [39,40]. Finally, Akt1 and
Akt2 have been shown to function in an opposing manner
in the regulation of breast cancer cell invasive migration.
(Irie et al., 2005).
The Skp2 Ser72 Akt phosphorylation site is 
conserved in large mammals
Following these clues, we and others recently demon-
strated that elevated Akt activity could positively influence
Skp2 activity, and impair its destruction by the APC/Cdh1
E3 ubiquitin ligase complex [41,42] (Figure 1). At first
glance, this offers a molecular mechanism for the fre-
quently observed Skp2 overexpression in many human
cancers and links this phenomenon to the abnormal acti-
vation of the PI 3-K and Akt pathway, which is well-docu-
mented as being aberrantly activated in the majority of
human cancers. The Ser72 site is conserved in most large
mammals we examined, including primates, dogs, horses,
pigs, cows, and even rats. However, this putative Ser72 Akt
phosphorylation site is not present in the mouse
sequence. It is known that similar inter-species differences
also exist for other Akt substrates including p27 [36] and
caspase-9 [43]. We further found that the Ser72 site is not
conserved in Xenopus or Zebrafish, thus indicating that
the Akt/Skp2 regulatory pathway might have evolved as a
gain-of-function event later in evolution. On the other
hand, it is well-established that tumorigenesis differs dra-
matically between humans and mice [44]. Hence, it is
plausible that for large animals with a longer life span
than mice, which requires more cell division events, an
additional layer of cell cycle control is developed. It is also
Schematic model for how Akt1-dependent phosphorylation of Skp2 at the Ser72 site promotes Skp2 cytoplasmic localization  and stabilizes Skp2 by impairing its association with the APC/Cdh1 E3 ubiquitin ligase complex Figure 1
Schematic model for how Akt1-dependent phosphorylation of Skp2 at the Ser72 site promotes Skp2 cytoplas-
mic localization and stabilizes Skp2 by impairing its association with the APC/Cdh1 E3 ubiquitin ligase com-
plex. Phosphorylation of Skp2 at Ser72 by Akt1 greatly reduces its ability to interact with the importin complex as well as 
promotes its association with 14-3-3, resulting in cytoplasmic retention. Furthermore, phosphorylation of Skp2 by Akt1 primes 
Skp2 for subsequent phosphorylation of Ser75 by Casein Kinase I (CKI). Phosphorylation on both Ser72 and Ser75 results in 
impaired association with Cdh1, thus allowing Skp2 to escape APC/Cdh1-mediated ubiquitination and destruction.Cell Division 2009, 4:11 http://www.celldiv.com/content/4/1/11
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possible that there is another universal molecular mecha-
nism shared by most species to control Skp2 stability/
activity, which is not identified yet.
The potential role for Casein Kinase I in Skp2 
stability control
Our results further demonstrate that phosphorylation of
human Skp2 at Ser72 creates a priming site, and that CKI
may be one of the kinases which phosphorylates Ser75, a
process that would lead to subsequent dissociation from
Cdh1 and stabilization of Skp2. Sequence analysis also
reveals that the Ser75 site is not conserved in all mammals
we examined; although most large mammals contain
Ser72, they do not contain Ser75, which is replaced by an
Asn. This indicates that CKI or other Ser75 kinases are not
likely to efficiently phosphorylate Skp2 in these species.
Clearly additional studies are required to examine in more
detail the regulation of Ser75 phosphorylation in human
Skp2, and to determine if CKI is the physiologically-rele-
vant kinase, and similarly whether Akt regulates Skp2 sta-
bility in species that do not harbor Ser75.
Regardless, our data clearly points to an important dis-
tinction between human and mouse Skp2 regulation by
the Akt pathway. First, phosphorylation of Ser72 is critical
for the ability of Akt to regulate Skp2 stability. Since
mouse Skp2 does not contain this site, it explains why
mouse Skp2 expression is not affected by the Akt pathway.
Secondly, additional experiments using human Skp2 have
revealed distinct contributions of phosphorylation events
to Skp2 stability. Phosphorylation of Ser72 by Akt is suffi-
cient to disrupt the association between importin and
Skp2, leading to Skp2 cytoplasmic translocation. Moreo-
ver, phosphorylation of both Ser72 and Ser75 by Akt1 and
CKI, respectively, is required to disrupt the association
between Cdh1 and Skp2, thus stabilizing Skp2. However,
since Cdh1 is primarily localized in the nucleus, phospho-
rylation of Skp2 by Akt itself might be sufficient to stabi-
lize a portion of Skp2 by cytoplasmic translocation.
Akt1 regulates both Skp2 stability and Skp2 
transcription
Our data argues that the function of Akt at regulating Skp2
levels is primarily through the regulation of Skp2 protein
stability. Substitution of the Ser72 residue to a non-phos-
phorylatable Ala created a much more unstable Skp2 pro-
tein. Conversely, the phospho-mimetic S72D/S75D Skp2
mutant is much more stable than the wild-type protein.
This is likely due to the ability of Akt to affect Cdh1-medi-
ated Skp2 degradation since the S72D/S75D mutant
resists degradation, and because Akt failed to protect the
S72A mutant from degradation. Moreover, in cells where
Akt1 is depleted, reduced phosphorylation of Ser72 in
Skp2 correlates with a marked decrease in Skp2 levels.
This process is likely due to enhanced Skp2 degradation
by Cdh1, since inactivation of Cdh1 resulted in restora-
tion of Skp2 to a level comparable to control siRNA-
treated samples. Our results do not necessarily disagree
with a recent report which showed that activation of PI 3-
K and Akt also influences Skp2 mRNA levels [45]. It has
been shown that Skp2 is a downstream target of E2F-1
[46], and thus the regulation of its expression at the level
of transcription is higher in cells in which Rb is defective.
It has also been reported that activation of Akt promotes
the binding of E2F-1 to the proximal Skp2 promoter [47].
Therefore, Skp2 upregulation in most human cancers
might be due to a synergistic action of upregulated Skp2
mRNA levels with a concomitant evasion of Cdh1-medi-
ated degradation.
Does Akt regulate other APC/Cdh1 substrates 
other than Skp2?
For most SCF/F-box complexes, the regulation of sub-
strate recognition occurs at the level of the substrate, such
that the F-box protein will usually not recognize its down-
stream substrates without a specific combination of phos-
phorylation events. On the other hand, the interaction of
Cdh1 and Cdc20 with their substrates usually does not
require any post-translational modifications [48]. In this
case, the regulation of APC activity occurs primarily on the
APC complex itself. Phosphorylation of Cdc20 by Plk and
Cdc2/Cyclin B is required for the activation of the APC/
Cdc20 complex while phosphorylation of Cdh1 by the
Cdk2/Cyclin A complex terminates Cdh1 activity by dis-
sociating Cdh1 from the APC core subunits [49]. Recently,
it was shown that APC/Cdh1 ubiquitinates and degrades
its substrates with different kinetics, and the preference of
degradation order depends on the relative processivity of
substrate multiubiquitination by APC/Cdh1 [50].
Our finding provides another unique mechanism for the
selective degradation of Cdh1 downstream targets. In all
the known Cdh1 substrates tested so far, only Skp2
expression levels are affected by Akt signaling. This pro-
vides a novel link between p27 degradation and Akt acti-
vation, both of which can be induced by growth factors.
Unlike most E3 ubiquitin ligases, Cdh1 is active in a low-
kinase state during early G1 and in quiescent cells. Thus it
is assumed that Cdh1 plays a major role in the mainte-
nance of quiescence [51]. It is also known that most cells
in human tissues are in a differentiated (post-mitotic)
state, and in many cases loss of this differentiated state
plays a major role in promoting tumorigenesis, and p27
has been demonstrated to be a critical player. KPC has
been shown to play an important role in triggering the
degradation of p27 in the early G1 phase [52]. Further-
more, Skp2-governed p27 degradation is critical for the
timely activation of Cdk2 activity, and subsequent transi-
tion through the restriction point. Consistent with a pre-
vious report [5], our own studies show that activation ofCell Division 2009, 4:11 http://www.celldiv.com/content/4/1/11
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Akt upon serum stimulation allows for the early induction
of Skp2, which correlates with p27 disappearance. This
protective mechanism mediated by the Akt pathway is
very similar to the Cdk2/cyclin E complex, which protects
Cdc6 from Cdh1-mediated destruction [53]. Thus, our
finding expands our knowledge of how specific kinase
cascades could influence Cdh1-governed proteolysis. In
contrast to the SCF complex, where phosphorylation trig-
gers substrate recognition, we propose that a specific
phosphorylation event by Akt, in addition to CKI, disa-
bles the degradation mediated by APC/Cdh1. Upon
Cdk2/cyclin E phosphorylation, the interaction between
Cdh1 and Cdc6 is reduced [53]. Similar to their finding,
we found that the interaction between Skp2 and Cdh1 is
also affected by Akt phosphorylation.
The next outstanding question is whether Akt could affect
the stability of other APC/Cdh1 substrates. We found that
manipulation of Akt activity does not affect the expression
of other known Cdh1 substrates we examined, including
Cdc20, Plk-1, Geminin, Cdc6, Securin, cyclin A and cyclin
B [3,49]. These results indicate that Akt might only specif-
ically affects the destruction of a subgroup of Cdh1 sub-
strates including Skp2 and others that are still
unidentified. We used the Scansite program to screen all
known Cdh1 downstream targets, and found that except
for Cdc25A and DNMT1, none of the other Cdh1 sub-
strates contains the canonical Akt site. Therefore, it is
interesting to further investigate whether depletion of
Akt1 results in decreased expression of both Cdc25A and
DNMT1. Furthermore, similar to what Akt does to Skp2,
whether elevated Akt activity protects Cdc25A and
DNMT1 from Cdh1-mediated destruction.
Akt promotes Skp2 cytoplasmic translocation
The Akt pathway functions to promote both cell survival
and cell growth by inactivating many of its downstream
substrates [23]. Interestingly, by the same token, phos-
phorylation of Akt substrates usually results in their cyto-
plasmic translocation. In the case of p27, p21 and FOXO
proteins, the Akt phosphorylation site is proximal to the
Nuclear Localization Sequence (NLS) and when phospho-
rylated creates a binding site that can be recognized by the
14-3-3 proteins. Recruitment of 14-3-3 results in the
masking of the NLS and subsequent cytoplasmic translo-
cation [54]. We also observed an interaction of 14-3-3
with Skp2 in cells expressing activated Akt. However,
Ser72 phosphorylation per se is not sufficient for recruit-
ment of 14-3-3. Thus it is possible that 14-3-3 is recruited
to Skp2 after additional Akt phosphorylation events, or
indirectly through interaction with Akt. The NLS of Skp2
resembles that of SV40 T antigen, which is recognized by
the importin complex, the only difference being that Skp2
harbors the Ser72 Akt site. We also demonstrated that
deletion of the NLS results in cytoplasmic localization,
indicating the requirement of this sequence for nuclear
import. Moreover, in vitro biochemical analyses demon-
strated that deletion of the NLS disrupts the association
between Skp2 and importin, providing further evidence
that the specific association between Skp2 and the impor-
tin complex requires the NLS. Alternatively, the phospho-
rylation of serine or threonine residues by specific kinases
within the NLS could impair the interaction between the
importin complex and the NLS [55,56]. In keeping with
this notion, we also demonstrated that phosphorylation
of human Skp2 by Akt at Ser72 greatly reduces the inter-
action between Skp2 and importin. It is possible that both
of these mechanisms contribute to the cytoplasmic trans-
location of Skp2 subsequent to Akt phosphorylation. This
process is likely to be important for Skp2 function because
Akt phosphorylation of the Skp2 downstream targets p27,
p21 and FOXO1 also promotes their cytoplasmic localiza-
tion, thus terminating their function. Our findings add a
new dimension to this model by suggesting that Akt-
Sequence alignment of the Skp2 and Skp2B proteins reveals that there is an additional potential Akt phosphorylation site at the  C-terminus of the Skp2B protein Figure 2
Sequence alignment of the Skp2 and Skp2B proteins reveals that there is an additional potential Akt phospho-
rylation site at the C-terminus of the Skp2B protein.Cell Division 2009, 4:11 http://www.celldiv.com/content/4/1/11
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induced cytoplasmic translocation of Skp2 may lead to
elevated degradation of its downstream targets by the
cytoplasmic SCF/Skp2 complex. Lin et al suggested that
cytoplasmic Skp2 plays an important role in promoting
cellular motility [42]. It is well documented that cytoplas-
mic Skp2 is frequently observed in more advanced breast
and prostate cancer. Therefore, it is plausible that cyto-
plasmic Skp2 activity promotes metastasis. It is important
to further elucidate the novel substrates for cytoplasmic
Skp2, which will provide important insight for developing
new anti-cancer treatments.
Akt isoform specificity in the regulation of Skp2 
protein stability
Interestingly, our data points to Akt isoform specificity in
the regulation of Skp2 protein stability. Using siRNA's, we
found that Akt1, but not Akt2, is responsible for phospho-
rylation of Skp2 at Ser72, and in turn, modulation of its
protein stability. Furthermore, we demonstrated that
when overexpressed in 293T cells, human Skp2 specifi-
cally interacts with endogenous Akt1, but not Akt2.
Although the precise mechanism by which Akt1 can,
whereas Akt2 cannot, signal to Skp2 has yet to be defined,
and likely mechanisms include the localization of distinct
Akt isoforms in cells and tissues. It is plausible that the
nuclear localization of Akt1 which has been observed in
some cell lines may allow it to interact with nuclear Skp2
and promote nuclear export, and that the more cytoplas-
mic localization of Akt2 may restrict its accessibility to
Skp2. Although these and other possibilities have yet to be
tested, our data is consistent with the recent finding that
only Akt1 promotes G1 progression, DNA synthesis and
proliferation of C2 myoblasts, whereas Akt2 is primarily
required for exit from mitosis [38].
Is Skp2B a better substrate for Akt?
Skp2 cytoplasmic localization has been observed in many
clinical tumor samples and is correlated with aggressive
malignancy and poor diagnosis [15,57-60]. Our results
offer a molecular mechanism for the cytoplasmic localiza-
tion of Skp2. Furthermore, since elevated Akt also inacti-
vates the Bad, Caspase-9 and FOXO proteins to allow
tumor cells to evade the apoptosis pathway, cancer cells
with cytoplasmic Skp2 localization tend to be more
advanced. Recently, another novel Skp2 splicing isoform
(Skp2B) was identified, which possesses many distinct
molecular properties because it differs from the Skp2 pro-
tein at the carboxyl-terminus [61]. One major difference is
that in contrast with the nuclear localization of Skp2,
Skp2B localizes to the cytoplasm [58]. Comparing the
Skp2 and Skp2B sequences showed that Skp2B contains
the identified NLS, and does not have an obvious nucleus
export signal (NES) sequence at its unique carboxyl-termi-
nus. However, Skp2B contains an additional high proba-
bility Akt site in this region (Figure 2). This might make
Skp2B an extremely effective strong substrate for Akt,
which could result in cytoplasmic translocation by
unknown mechanism.
Concluding remarks
Collectively, we and others provide evidence that Akt
directly controls Skp2 stability and oncogenic activity. We
identified one major Akt phosphorylation site on Skp2 at
Ser72 that is located within a putative Nuclear Localiza-
tion Sequence (NLS). We demonstrated that phosphoryla-
tion of Ser72 by Akt1, but not Akt2, promotes Skp2
cytoplasmic translocation, likely due to a disruption of
the NLS. This finding provides an explanation for previ-
ous observations whereby cytoplasmic Skp2 staining is
detected in tissues from advanced breast and prostate can-
cer. Thus in cells released from serum-starvation, elevated
Akt activity in the early G1 phase protects Skp2 from con-
stitutive degradation by Cdh1. Hence, our finding
expands our knowledge of how specific kinase cascades
influence proteolysis governed by the APC/Cdh1 com-
plex. In addition, these findings provide insight into how
the activated PI3-K/Akt pathway leads to elevated Skp2
expression and subsequent enhanced p27 destruction in
human cancers, providing further evidence that elevated
Akt activity and cytoplasmic Skp2 expression may be caus-
ative for breast and prostate cancer progression. These
results may provide a rationale to develop specific Akt1
inhibitors as efficient anti-cancer drugs.
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